Skip to main content
Fig. 5 | Journal of Ovarian Research

Fig. 5

From: Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells

Fig. 5

In vitro molecular effects of Dasatinib, Gefitinib or a combination of both drugs in HOAC signaling pathways. HOAC were treated 2 h or 24 h with Dasatinib (Da), Gefitinib (Ge) (0.1 × IC50 of each cell line after 72 h of treatment) or an equieffective combination of Dasatinib and Gefitinib (Da + Ge) (0.1 × IC50 of each drug alone). The EGFR, phospho-EGFR, c-Src, phospho-c-Src, ERK, phospho-ERK, Akt, phospho-Akt (p-Akt) and β-actin levels were determined by western blot using specific antibodies. Immunocomplexes were visualized by autoradiography

Back to article page